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Many cancer cells require exogenous glutamine for proliferation, supply of TCA cycle intermediates, lipid
synthesis, mTOR activity, and neutralization of reactive oxygen species. In this issue of Cancer Cell, Jeon
and colleagues identify chemotherapy-induced endoplasmic reticulum stress as a novel strategy to target
glutamine dependence.Precision medicine postulates that under-
standing of the molecular circuitry of a
tumor facilitates selection of the most
appropriate therapy. Increasingly, atten-
tion in cancer research and drug develop-
ment is turning to the dynamic machinery
controlling proteostasis and metabolism.
In this issue of Cancer Cell, Jeon et al.
(2015) show that the tubulin-targeting
agent paclitaxel induces significant endo-
plasmic reticulum (ER) stress and protein
misfolding in breast cancer cells in vitro
and, as a consequence, promotes degra-
dation of the glutamine (Gln) transporters
SLC1A5 and SLC38A2.
The ER unfolded protein response
(UPR) is a stress-induced survival mecha-
nism utilized by tumors to buffer proteo-
toxic stress. Cancer cells rely on the ER
UPR to cope with numerous genetic and
proteotoxic insults, including hypoxia,
oxidative stress, genetic instability, and
the overexpression of numerous wild-
type or mutant oncoproteins. Overloading
the UPR can result in catastrophic ER
stress and cell death (Wang andKaufman,
2014). The authors observed that pro-
teosomal degradation of SLC1A5 and
SLC38A2 required ER stress-dependent
activation of the ER-associated ubiquitin
ligase RNF5.
Breast cancer cells are generally char-
acterized by an increased dependence
on Gln for tricarboxylic acid cycle (TCA)
intermediates, cellular energetics, reac-
tive oxygen species (ROS) buffering, lipid
synthesis, mTOR activity, and autophagy
(which is inhibited by mTOR, see Figure 1)
(Hensley et al., 2013). Jeon et al. (2015)
report that Rnf5-deficient mouse mam-
mary tumors were less differentiated and
expressed elevated SLC1A5 protein,
while RNF5 depletion in a human breastcancer cell line enhanced tumorigenesis
and abrogated the cells’ response to
paclitaxel. Silencing of the Gln trans-
porters had the opposite effect, support-
ing the importance of RNF5-mediated
suppression of SLC1A5/38A2 levels as a
mediator of this phenotype. Further,
RNF5-dependent modulation of SLC1A5
reduced mTOR activity and promoted
autophagy and cell death in response to
ER stress.
Based on their analysis showing that an
expression profile of RNF5hi/SLC1A5/
38A2lo in luminal breast cancer is associ-
ated with a favorable prognosis, Jeon
et al. (2015) propose that it may be
possible to use this phenotype to identify
those patients whose breast cancer is
likely to respond optimally to ER stress-
inducing therapies such as paclitaxel.
Although the current study finds that
high SLC1A5 expression correlated with
poor response to neoadjuvant therapy, it
found that, in greater than 60% of breast
cancers, regulation of SLC1A5/38A2
expression did not appear to be under
the control of RNF5 and thus not likely
sensitive to ER stress. Further, other
data suggest that luminal-type breast
cancers are more likely to be Gln insensi-
tive, while basal-type breast cancers are
more frequently Gln-dependent (Hensley
et al., 2013). Given this complexity, pa-
tient stratification to either ER stress
inducing agents or strategies to interfere
with Gln uptake or metabolism would
benefit from a more direct assessment
of tumor Gln dependence, as was
recently described in gliomas using Gln-
based PET imaging (Venneti et al., 2015).
Pharmacologic modulation of the ER
UPR represents a viable strategy for can-
cer therapy. Several agents, includingCancer Cellproteasome inhibitors and heat shock
protein 90 (Hsp90) inhibitors are being
used to exploit this vulnerability (Wang
and Kaufman, 2014). A small molecule in-
hibitor of SLC1A5, gamma-l-glutamyl-p-
nitroanilide (GPNA, see Figure 1), is under
preclinical investigation and a gluta-
minase (GLS, see Figure 1) inhibitor (CB-
839) is currently being evaluated in phase
I clinical trials in cancer patients (see
https://www.clinicaltrials.gov/). Targeting
multiple signaling pathways with combi-
nation therapy also represents a unique
approach to prevent/delay treatment
resistance. The data from Jeon et al.
(2015) suggest that increased efficacy in
Gln-dependent cancers may be achieved
by combining agents that induce cata-
strophic ER stress with drugs that inter-
fere with Gln uptake or metabolism. For
example, although each agent as amono-
therapy is efficacious, the combination of
paclitaxel and CB-839 is superior to either
agent alone in triple negative breast can-
cer (Gross et al., 2014). The result of inhib-
iting glutaminase is 2-fold: less glutamate
for the TCA cycle and less glutathione to
buffer ROS, itself an inducer of the ER
UPR. Thus, the activity of this drug combi-
nation in breast cancer supports induction
of catastrophic ER stress concomitant
with reduced Gln metabolism as a thera-
peutic strategy. This paradigm can be
exploited with other ER stress-inducing
agents. For example, Hsp90 inhibitors
induce catastrophic ER stress because
two effectors of the UPR, inositol-
requiring enzyme 1a (IRE1a) and protein
kinase RNA-like endoplasmic reticulum
kinase (PERK), are Hsp90 client pro-
teins that are destabilized upon Hsp90
inhibition (Marcu et al., 2002). Hsp90 in-
hibitor-mediated proteotoxic stress in27, March 9, 2015 ª2015 Elsevier Inc. 317
Figure 1. Glutamine Transport and Metabolism in Cancer Cells and the Consequences of
Their Inhibition
Depriving breast cancer cells of Gln via ER stress (paclitaxel) occurs by RNA5-mediated degradation of
the Gln importers SLC1A5/SLC38A2. Gln import is also inhibited by the small molecule GPNA, which
causes concomitant stabilization of the lactate importer MCT1. Because breast cancer cells are addicted
to Gln, inhibition of Gln uptake ultimately leads to catastrophic ER stress and cell death. Reduced intra-
cellular Gln decreases the energy output of the TCA cycle and inhibits lipid and non-essential amino
acid (NEAA) synthesis. Gln deprivation also leads to reduction in glutathione levels and increased oxidative
stress, which further taxes the ER UPR. Finally, the subsequent decreased activity of mTORC1 inhibits
growth-promoting pathways, while inducing autophagy to catabolize/recycle nutrients and promote cell
survival. Cancer cells may utilize autophagy to adapt to prolonged Gln deprivation therapy. a-KG,
a-ketoglutarate.
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tor BPTES (bis-2-(5-phenylacetamido-
1,2,4- thiadiazol-2-yl)ethyl sulfide) was
recently shown to cause dramatic cyto-
toxicity in cells with constitutively high
mTOR activity (Li et al., 2015). It would
be worthwhile to determine whether the
cytotoxicity associated with RNF5-medi-
ated SLC1A5 degradation is greatest in
breast cancer cells with elevated mTOR
activity. As the authors’ data show,
mTOR expression decreases following
RNF5-mediated SLC1A5 degradation,
while autophagy is increased.
Although disruption of Gln metabolism
delays breast cancer growth in animal
models, Gln insensitive breast cancer
cells can be selected for (Hensley
et al., 2013). These populations possess318 Cancer Cell 27, March 9, 2015 ª2015 Elsincreased metastatic potential and thera-
peutic resistance. This phenotype may
be mediated by utilization of increased
lactate uptake to compensate for altered
Gln metabolism (see below). Further, can-
cer cells can compensate for reduced Gln
uptake by synthesizing the amino acid
de novo and utilizing the bidirectional
transporter SLC7A5/SLC3A2 to simulta-
neously efflux excess Gln and import
other essential amino acids (Nicklin
et al., 2009). Such observations highlight
possible unintended consequences of
anti-Gln based therapy that will require
further exploration.
Tumor microenvironment plays a crit-
ical role in cancer development. Dynamic
interaction among cancer-associated
stromal cells (smooth muscle cells, fibro-evier Inc.blasts, immune cells, endothelial cells,
etc.) and adjacent cancer cells have
been shown to promote malignancy.
Thus, crosstalk between the cancer-
associated stroma and cancer cells is
an additional therapeutic consideration
(Wang and Kaufman, 2014). Compared
to normal stroma, cancer-associated
fibroblasts (CAFs) display reduced
c-Myc activity. Because c-Myc regulates
expression of Gln transporters (Hensley
et al., 2013), the subsequent shift in Gln
metabolism in CAFs lowers their intracel-
lular glutathione levels, which in turn pro-
motes an oxidizing environment that
favors secretion of stromally-produced
growth factors that enhance epithelial
tumorigenesis (Valencia et al., 2014).
Although Jeon et al. (2015) show that
paclitaxel reduces mTOR activity in
breast cancer epithelial cells, a similar
effect of paclitaxel on the tumor stroma
could push the cancer cells toward a
more aggressive phenotype.
Studies have suggested that a ‘‘lactate
shuttle’’ exists in the tumor microenviron-
ment (Doherty and Cleveland, 2013). The
high glycolytic activity of CAFs results
in lactate accumulation which they
then secrete into the extracellular space
where it can be taken up by adjacent
cancer cells, which use lactate to
drive energy production via oxidative
phosphorylation in mitochondria while
increasing levels of NADH. Reduction of
Gln uptake with the SLC1A5 inhibitor
GPNA enhances stability of the mono-
carboxylate transporter MCT1, which is
responsible for transporting lactate into
cells (see Figure 1). Whether this is a
direct off-target effect of GPNA or repre-
sents an adaptive cellular response to
reduced Gln uptake remains to be deter-
mined, but it should be examined in
the context of RNF5-mediated SLC1A5
degradation because it may reflect
an additional potential mechanism
of acquired resistance to Gln pathway
targeting.
A better understanding of themolecular
determinants of Gln addiction, the conse-
quences of disrupting Gln metabolism
on cancer cell viability, and the various
mechanisms of resistance available to
cancer cells is vital to the optimal target-
ing of this metabolic pathway in vivo.
The data provided in the current study
by Jeon et al. (2015) identify a role for
ER stress in augmenting the cellular
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suggest novel patient stratification and
treatment strategies in breast cancer
and other malignancies.REFERENCES
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In this issue of Cancer Cell, Rubio-Perez and colleagues present an in silico prescription strategy based on
identifying somatic driver alterations and druggability options. Although relatively few patients were found
treatable following current clinical guidelines, many more could benefit from drug repurposing, considering
compounds at various stages of (pre-)clinical investigation.Precision oncology aims to provide clin-
ical management tailored toward the
molecular characteristics of the patient’s
tumor (Garraway et al., 2013) and was
defined as a priority by the US govern-
ment through the recently announced
Precision Medicine Initiative. Molecular
characterization efforts such as The
Cancer Genome Atlas (TCGA) have laid
the foundation for precision oncology.
At present, TCGA has analyzed over
11,000 tumors from 34 cancer types,
which identified somatic and germ-line
aberrations including single nucleotide
variants, DNA copy number alterations,
fusion genes, epigenetic modifications,
and gene expression signatures. Now
that the molecular landscape has been
defined for many tumor types, a challenge
remains to associate these alterations
with current therapies in the appropriate
clinical context. Agents targeting mole-
cular defects are part of the standardof care for subsets of tumors such as
melanoma, lung cancer, and chronic
myeloid leukemia, but the potential
benefit of targeted therapies across can-
cer is unknown.
In this issue of Cancer Cell, Rubio-
Perez et al. (2015) propose a three-step
in silico drug prescription strategy that
connects patients to therapeutic regi-
mens targeting the tumors’ genomic alter-
ations (Figure 1). First, somatic alterations
in genes predicted to drive tumorigenesis
were detected in 6,792 tumor samples
across 28 cancer types, which included
4,068 tumors from 16 TCGA studies.
Part of the analysis included somatic
point mutations and small insertions/dele-
tions, focal DNA copy number alterations,
and transcript fusions for TCGA samples,
but they were limited to mutations only for
non-TCGA cohorts. Using three statistical
methods, genes under positive selection
were identified, which resulted in a listof 459 significantly altered genes. Sec-
ond, all gene alterations were classified
as loss of function or activating. Third,
therapeutic agents targeting each driver
gene directly, indirectly, or through gene
therapy were collected. This included
all Food and Drug Administration (FDA)-
approved drugs, therapies being evalu-
ated in clinical trials, and compounds
supported by preclinical data. Finally,
drugs were matched with somatic alter-
ations that were predicted to result in
gene activation in order to link patients
with a targeted therapy.
Using this approach, Rubio-Perez et al.
(2015) found that only 5.9%of the patients
could potentially benefit from approved
therapies following standard clinical
guidelines; a similar percentage of
oncology patients are treated on thera-
peutic clinical trials. However, this initial
result did not consider the many clinical
trials designed to evaluate targeted27, March 9, 2015 ª2015 Elsevier Inc. 319
